Scientists have revealed a drug which might be able to block the Ebola virus infection and stop the progress of the deadly disease.
Lijun Rong of the University of Illinois and his colleagues found that Ebola virus use a gateway called G protein-coupled receptors, or GPCRs, to enter a cell after attaching to its surface. Blocking entry with a drug that ties up the receptor may prove to be an effective therapy.
Rong said that these G protein-coupled receptors were a big family of closely related molecules in humans, adding that about half of their drugs were developed to target GPCRs.
In the study, Rong found that 20 GPCR antagonists, or molecules that block GPCR receptors, were able to block Ebola and Marburg viruses from entering cells.
Rong further said that learning how the two viruses infect cells and how they could be blocked offers the hope of finding therapeutics to combat both deadly diseases.
The study is published in the Journal of Virology.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
